Vandetanib is a selective and potent inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (RE-arranged during Transfection) tyrosine kinases.
EGFR- and VEGFR-dependent signaling are both clinically validated pathways in cancer, including non-small-cell lung cancer. RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer led to orphan-drug designation by the regulatory authorities in the USA and EU.
It indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
*Use in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks.